Vertex Pharmaceuticals (VRTX) data in the lumbosacral radiculopathy pain trial is likely to be seen as disappointing, as there does not seem to be any difference with placebo in pain reduction, Wells Fargo analyst Mohit Bansal tells investors in a research note. The firm, which made no change to its Overweight rating or $555 price target says the stock could be 10% on the news.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex price target lowered to $535 from $600 at H.C. Wainwright
- Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
- Oppenheimer downgrades Vertex after lumbosacral radiculopathy study
- Vertex Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- Vertex Pharmaceuticals price target lowered to $400 from $451 at RBC Capital